RxDoctor Payments Data

Siddharth Kapoor, MD

Neurology · Edison, NJNPI 1275635849

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,231 of the $10,008 with a category attached, or 82.2%. Amgen accounts for 91.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $8,415 and has fallen 99.4% since, to $52 in 2025.

$10,008in general payments, 2019–2025

Across 20 payments — averaging $500.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$9K
  • AbbVie$400
  • Neuropace, Inc.$366
  • Zimmer Biomet$57
  • Bristol Myers Squibb$52
$77,291in research payments, 2019–2025

Across 10 payments — averaging $7729.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GW Research Limited$48K
  • Amgen$20K
  • SK Life Science, Inc.$5K
  • UCB Biosciences Inc.$4K

What the payments were for

  • Speaking & faculty fees$8,23182%
  • Travel & lodging$9299%
  • Food & beverage$8488%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen12$9,133
AbbVie1$400
Neuropace, Inc.3$366
Zimmer Biomet1$57
Bristol Myers Squibb3$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,008 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,917
Medicare patients
74
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)15$101,320
UbrelvyUbrogepant57$68,745
QuliptaAtogepant57$64,473
XcopriCenobamate39$42,419
BriviactBrivaracetam20$33,902
VimpatLacosamide16$30,231
AptiomEslicarbazepine Acetate15$30,224
Nurtec OdtRimegepant Sulfate29$27,155
Aimovig AutoinjectorErenumab-Aooe24$24,115
Emgality PenGalcanezumab-Gnlm21$17,681
Lacosamide48$8,586
Oxcarbazepine68$8,353
Levetiracetam191$7,893
Clobazam23$5,265
Divalproex Sodium ErDivalproex Sodium24$4,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$400$133,218114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →